tetano
Editor, Senior Moderator
Influenza Other Respir Viruses
. 2024 Aug;18(8):e13360.
doi: 10.1111/irv.13360. Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024
Liliana Antunes[SUP] 1 [/SUP], Clara Mazagatos[SUP] 2 3 [/SUP], Iván Martínez-Baz[SUP] 3 4 [/SUP], Reinout Naesens[SUP] 5 [/SUP], Maria-Louise Borg[SUP] 6 [/SUP], Goranka Petrović[SUP] 7 [/SUP], Terra Fatukasi[SUP] 8 [/SUP], Ligita Jancoriene[SUP] 9 [/SUP], Ausenda Machado[SUP] 10 [/SUP], Beatrix Oroszi[SUP] 11 [/SUP], Petr Husa[SUP] 12 [/SUP], Mihaela Lazar[SUP] 13 [/SUP], Ralf Dürrwald[SUP] 14 [/SUP], Jennifer Howard[SUP] 1 [/SUP], Aryse Melo[SUP] 15 [/SUP], Gloria Pérez-Gimeno[SUP] 2 3 [/SUP], Jesús Castilla[SUP] 3 4 [/SUP], Eva Bernaert[SUP] 5 [/SUP], Aušra Džiugytė[SUP] 6 [/SUP], Zvjezdana Lovrić Makarić[SUP] 7 [/SUP], Margaret Fitzgerald[SUP] 8 [/SUP], Auksė Mickienė[SUP] 16 [/SUP], Verónica Gomez[SUP] 10 [/SUP], Gergő Túri[SUP] 11 [/SUP], Lenka Součková[SUP] 12 [/SUP], Alexandru Marin[SUP] 17 [/SUP], Kristin Tolksdorf[SUP] 18 [/SUP], Nathalie Nicolay[SUP] 19 [/SUP], Angela M C Rose[SUP] 1 [/SUP]; European Hospital Vaccine Effectiveness Group
Affiliations
We conducted a multicentre test-negative case-control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14-29 days and 40% at 60-105 days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, with VE > 70% in older adults (≥ 65 years) up to 1 month post vaccination.
Keywords: COVID‐19 XBB.1.5 vaccine; Europe; SARS‐CoV‐2 hospitalisation; vaccine effectiveness.
. 2024 Aug;18(8):e13360.
doi: 10.1111/irv.13360. Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024
Liliana Antunes[SUP] 1 [/SUP], Clara Mazagatos[SUP] 2 3 [/SUP], Iván Martínez-Baz[SUP] 3 4 [/SUP], Reinout Naesens[SUP] 5 [/SUP], Maria-Louise Borg[SUP] 6 [/SUP], Goranka Petrović[SUP] 7 [/SUP], Terra Fatukasi[SUP] 8 [/SUP], Ligita Jancoriene[SUP] 9 [/SUP], Ausenda Machado[SUP] 10 [/SUP], Beatrix Oroszi[SUP] 11 [/SUP], Petr Husa[SUP] 12 [/SUP], Mihaela Lazar[SUP] 13 [/SUP], Ralf Dürrwald[SUP] 14 [/SUP], Jennifer Howard[SUP] 1 [/SUP], Aryse Melo[SUP] 15 [/SUP], Gloria Pérez-Gimeno[SUP] 2 3 [/SUP], Jesús Castilla[SUP] 3 4 [/SUP], Eva Bernaert[SUP] 5 [/SUP], Aušra Džiugytė[SUP] 6 [/SUP], Zvjezdana Lovrić Makarić[SUP] 7 [/SUP], Margaret Fitzgerald[SUP] 8 [/SUP], Auksė Mickienė[SUP] 16 [/SUP], Verónica Gomez[SUP] 10 [/SUP], Gergő Túri[SUP] 11 [/SUP], Lenka Součková[SUP] 12 [/SUP], Alexandru Marin[SUP] 17 [/SUP], Kristin Tolksdorf[SUP] 18 [/SUP], Nathalie Nicolay[SUP] 19 [/SUP], Angela M C Rose[SUP] 1 [/SUP]; European Hospital Vaccine Effectiveness Group
Affiliations
- PMID: 39145535
- DOI: 10.1111/irv.13360
We conducted a multicentre test-negative case-control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14-29 days and 40% at 60-105 days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, with VE > 70% in older adults (≥ 65 years) up to 1 month post vaccination.
Keywords: COVID‐19 XBB.1.5 vaccine; Europe; SARS‐CoV‐2 hospitalisation; vaccine effectiveness.